Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C26H41BrNO4.Br |
| Molecular Weight | 591.416 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Br-].COC1=C(OC)C=C(C[N+]4(CCOCC[C@@H]2CC[C@H]3C[C@@H]2C3(C)C)CCOCC4)C(Br)=C1
InChI
InChIKey=IKGXLCMLVINENI-QOXGANSBSA-M
InChI=1S/C26H41BrNO4.BrH/c1-26(2)21-6-5-19(22(26)16-21)7-11-31-12-8-28(9-13-32-14-10-28)18-20-15-24(29-3)25(30-4)17-23(20)27;/h15,17,19,21-22H,5-14,16,18H2,1-4H3;1H/q+1;/p-1/t19-,21-,22-;/m0./s1
| Molecular Formula | C26H41BrNO4 |
| Molecular Weight | 511.512 |
| Charge | 1 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 3 / 3 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | BrH |
| Molecular Weight | 80.912 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Pinaverium, known under the brand name DICETEL, is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function. It is shown to relieve GI spasm and pain, transit disturbances and other symptoms related to motility disorders and may be considered as effective first-lline therapy for patients with irritable bowel syndrome (IBS). Pinaverium is also used to help relieve symptoms caused by certain disorders of the gallbladder associated with secretion of bile. Pinaverium bromide is the common ingredient in formulations, mostly as oral tablets. Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada. DICETEL® (pinaverium bromide) is a calcium antagonist which inhibits the calcium influx by
blocking the voltage-dependent calcium channel at the smooth muscle cell level. It possesses a high degree of selectivity for the intestinal smooth muscle.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
| 1.75 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | Dicetel Approved UseDICETEL® (pinaverium bromide) is indicated:
- for the treatment and relief of symptoms associated with irritable bowel syndrome (IBS):
abdominal pain, bowel disturbances and intestinal discomfort.
- for the treatment of symptoms related to functional disorders of the biliary tract. |
|||
| Palliative | Dicetel Approved UseDICETEL® (pinaverium bromide) is indicated:
- for the treatment and relief of symptoms associated with irritable bowel syndrome (IBS):
abdominal pain, bowel disturbances and intestinal discomfort.
- for the treatment of symptoms related to functional disorders of the biliary tract. |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Contraction of human colonic circular smooth muscle cells is inhibited by the calcium channel blocker pinaverium bromide. | 2001 Jun |
|
| Increased calcium influx is responsible for the sustained mechanical tone in colon from dystrophic (mdx) mice. | 2001 May |
|
| [Current approaches to the diagnosis and treatment of irritable bowel syndrome]. | 2001 Sep-Dec |
|
| [Effects of dicetel on gastrointestinal motility and vegetative dysfunction in patients with duodenal ulcer]. | 2003 |
|
| Effect of pinaverium bromide on stress-induced colonic smooth muscle contractility disorder in rats. | 2003 Mar |
|
| [Randomized controlled clinical study on effect of Chinese compound changjitai in treating diarrheic irritable bowel syndrome]. | 2003 Nov |
|
| Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. | 2004 |
|
| [New approaches to diagnosing and treating hyperkinetic biliary dyskinesia associated with chronic acalculous cholecystitis]. | 2004 |
|
| [Drug treatment of irritable bowel syndrome: an unmet need]. | 2007 Mar |
|
| [Pinaverium bromide-induced esophageal ulcerations]. | 2008 Jan-Feb |
|
| Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. | 2008 Nov 13 |
|
| Effect of four medications associated with gastrointestinal motility on Oddi sphincter in the rabbit. | 2009 |
|
| Irritable bowel syndrome: a mild disorder; purely symptomatic treatment. | 2009 Apr |
|
| [Tiaohe Ganpi Hexin Decoction in treatment of irritable bowel syndrome with diarrhea: a randomized controlled trial]. | 2009 Sep |
|
| Effect of probiotic Lactobacillus (Lacidofil® cap) for the prevention of antibiotic-associated diarrhea: a prospective, randomized, double-blind, multicenter study. | 2010 Dec |
Patents
Sample Use Guides
The usual adult dosage is 50 mg three times a day (total daily dose of 150 mg). The dosage may be increased up to a maximum of 100 mg taken three times a day (maximum total daily dose of 300 mg).
It is recommended that the tablet be taken with a glass of water during meals or snacks. The tablet should not be swallowed when in the lying position or just before bedtime.
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:43:51 UTC 2023
by
admin
on
Sat Dec 16 17:43:51 UTC 2023
|
| Record UNII |
7SCF54H12J
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C333
Created by
admin on Sat Dec 16 17:43:51 UTC 2023 , Edited by admin on Sat Dec 16 17:43:51 UTC 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
145721938
Created by
admin on Sat Dec 16 17:43:51 UTC 2023 , Edited by admin on Sat Dec 16 17:43:51 UTC 2023
|
PRIMARY | |||
|
DTXSID2048614
Created by
admin on Sat Dec 16 17:43:51 UTC 2023 , Edited by admin on Sat Dec 16 17:43:51 UTC 2023
|
PRIMARY | |||
|
C116775
Created by
admin on Sat Dec 16 17:43:51 UTC 2023 , Edited by admin on Sat Dec 16 17:43:51 UTC 2023
|
PRIMARY | |||
|
54743
Created by
admin on Sat Dec 16 17:43:51 UTC 2023 , Edited by admin on Sat Dec 16 17:43:51 UTC 2023
|
PRIMARY | RxNorm | ||
|
7SCF54H12J
Created by
admin on Sat Dec 16 17:43:51 UTC 2023 , Edited by admin on Sat Dec 16 17:43:51 UTC 2023
|
PRIMARY | |||
|
DBSALT001130
Created by
admin on Sat Dec 16 17:43:51 UTC 2023 , Edited by admin on Sat Dec 16 17:43:51 UTC 2023
|
PRIMARY | |||
|
53251-94-8
Created by
admin on Sat Dec 16 17:43:51 UTC 2023 , Edited by admin on Sat Dec 16 17:43:51 UTC 2023
|
PRIMARY | |||
|
CHEMBL1909324
Created by
admin on Sat Dec 16 17:43:51 UTC 2023 , Edited by admin on Sat Dec 16 17:43:51 UTC 2023
|
PRIMARY | |||
|
100000081977
Created by
admin on Sat Dec 16 17:43:51 UTC 2023 , Edited by admin on Sat Dec 16 17:43:51 UTC 2023
|
PRIMARY | |||
|
1970218-70-2
Created by
admin on Sat Dec 16 17:43:51 UTC 2023 , Edited by admin on Sat Dec 16 17:43:51 UTC 2023
|
ALTERNATIVE | |||
|
Pinaverium bromide
Created by
admin on Sat Dec 16 17:43:51 UTC 2023 , Edited by admin on Sat Dec 16 17:43:51 UTC 2023
|
PRIMARY | |||
|
SUB09851MIG
Created by
admin on Sat Dec 16 17:43:51 UTC 2023 , Edited by admin on Sat Dec 16 17:43:51 UTC 2023
|
PRIMARY | |||
|
3696
Created by
admin on Sat Dec 16 17:43:51 UTC 2023 , Edited by admin on Sat Dec 16 17:43:51 UTC 2023
|
PRIMARY | |||
|
258-450-0
Created by
admin on Sat Dec 16 17:43:51 UTC 2023 , Edited by admin on Sat Dec 16 17:43:51 UTC 2023
|
PRIMARY | |||
|
m8822
Created by
admin on Sat Dec 16 17:43:51 UTC 2023 , Edited by admin on Sat Dec 16 17:43:51 UTC 2023
|
PRIMARY | Merck Index |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |